LABSLibrary / Longevity

GLP-1 Medications

What semaglutide and tirzepatide do, what the big trials found, and how to keep muscle and results for the long run.

Longevity5 min read5 sourcesUpdated Nov 15, 2026
14.9%Average loss on semaglutide (STEP 1)
20.9%Top-dose tirzepatide (SURMOUNT-1)
20%Fewer heart events (SELECT)
2/3Weight regained a year after stopping

Why it matters

GLP-1 medications changed obesity care in a few years. In large trials they cut body weight by roughly 15 to 21% and, in people with heart disease, reduced heart attacks and strokes. They also bring real trade-offs: a big share of the weight lost can be muscle, side effects are common, and most of the weight returns if you stop. The people who do best treat the drug as one tool alongside strength training, protein and sleep.

What the trials show

The headline numbers come from large, placebo-controlled trials in adults with obesity or overweight plus a weight-related condition.

Evidence 01

Semaglutide: about 15% of body weight

STEP 1, 1,961 adults, 68 weeks.

  • Average loss: 14.9% of body weight with weekly semaglutide 2.4 mg, versus 2.4% with placebo, alongside a lifestyle program.
  • Who lost what: 86% of people on semaglutide lost at least 5% of their weight, versus 31.5% on placebo.
  • Side effects: Mostly nausea and other gut symptoms; 4.5% stopped for gut side effects versus 0.8% on placebo.
Evidence 02

Tirzepatide: up to about 21%

SURMOUNT-1, 2,539 adults, 72 weeks.

  • Average loss: 15.0%, 19.5% and 20.9% of body weight on 5, 10 and 15 mg weekly, versus 3.1% with placebo.
  • How it differs: Tirzepatide acts on two gut hormone receptors (GLP-1 and GIP); semaglutide acts on one (GLP-1).
Evidence 03

Heart protection, not just weight

SELECT, 17,604 adults with heart disease and overweight but no diabetes.

  • Fewer heart attacks and strokes: Major cardiovascular events fell 20% with semaglutide (6.5% versus 8.0% over about three years).
  • Scope: Everyone in SELECT already had cardiovascular disease, so it does not show the same benefit in people without it.

The part most people miss

Protect your muscle

Any big weight loss takes some lean mass with it. On these drugs that share can be large, so build the habits that keep it.

Protocol 01

Lift two to three times a week

Resistance training is the signal that tells your body to keep muscle.

  • The number to know: In a STEP 1 body scan substudy, about 39% of the weight lost on semaglutide was lean mass, not fat.
  • What to do: Full-body strength sessions two to three times a week, with progressive load. See the strength training sheet.
Protocol 02

Hit a protein target every day

Appetite drops on these drugs, so protein has to come first on the plate.

  • How much: Use the protein calculator in LABS Tools; most active adults land between about 1.2 and 1.6 g per kg of body weight.
  • How: Protein first at each meal, and a protein-forward snack if a meal is small.

Plan for the long run

  • Expect regain if you stop: one year after stopping semaglutide in the STEP 1 extension, people regained about two-thirds of the weight they had lost.
  • Decide with your clinician whether you are treating a chronic condition (ongoing use) or a phase (with a plan to taper).
  • Keep the habits you build on the drug: training, protein, sleep and fiber are what hold results if the dose changes.
  • Use only FDA-approved products from a licensed pharmacy; compounded and online versions vary in quality.

Put it into practice

Your checklist

  • Talked with my clinician about whether a GLP-1 medication fits my goals and history
  • Strength training scheduled two to three times this week
  • Hit my daily protein target
  • Ate fiber and vegetables at two meals or more
  • Drank enough water (appetite cues are quieter on these drugs)
  • Logged side effects to raise at my next appointment
  • Have a plan for what happens if I stop or change dose

The evidence

Key sources

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.Find this source (opens Google Scholar in a new tab)
  2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.Find this source (opens Google Scholar in a new tab)
  3. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.Find this source (opens Google Scholar in a new tab)
  4. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553-1564.Find this source (opens Google Scholar in a new tab)
  5. Wilding JPH, et al. Impact of semaglutide 2.4 mg on body composition: a STEP 1 DEXA substudy. Presented at ABCD 2021.Find this source (opens Google Scholar in a new tab)

Education, not medical advice. Talk with your clinician before changing medication, supplements or training, especially if you are pregnant, managing a condition or taking prescriptions. Updated Nov 15, 2026.

Take the free LABS Score

Founding list

Make it a habit.

Join the founding list for the free New Year challenge: one lever at a time, with a cohort doing it alongside you.

  • December 2026: founding preview
  • January 2027: public launch and New Year challenge
  • January 2027: the LABS Tampa Retreat
What brings you to LABS? Choose any that fit.

Free. No card. We never sell your data.

Ask COACH